Tubulin nitration in human gliomas by FIORE G. et al.
Neuroscience Letters 394 (2006) 57–62
Tubulin nitration in human gliomas
Gabriella Fiore a, Carlo Di Cristo b, Gianluca Monti c, Angela Amoresano c, Laura Columbano d,
Pietro Pucci c, Fernando A. Cioffi d, Anna Di Cosmo b, Anna Palumbo a,∗, Marco d’Ischia c
a Zoological Station “Anton Dohrn”, Laboratory of Biochemistry and Molecular Biology, Villa Comunale, I-80121 Naples, Italy
b Department of Biological and Environmental Sciences, University of Sannio, Via Port’Arsa, 11, I-82100 Benevento, Italy
c Department of Organic Chemistry and Biochemistry, University of Naples Federico II, Via Cinthia 4, I-80126 Naples, Italy
d Department of Neurosurgery, Second University of Naples, c/o CTO, Viale Colli Aminei 21, 80131 Naples, Italy
Received 8 July 2005; received in revised form 30 September 2005; accepted 3 October 2005
Abstract
Immunohistochemical and biochemical investigations showed that significant protein nitration occurs in human gliomas, especially in grade IV
glioblastomas at the level of astrocytes and oligodendrocytes and neurones. Enhanced alpha-tubulin immunoreactivity was co-present in the same


























dass fingerprinting procedures demonstrated that tubulin is nitrated at Tyr224 in grade IV tumour samples but is unmodified in grade I samples
nd in non-cancerous brain tissue. These results provide the first characterisation of endogenously nitrated tubulin from human tumour samples.
2005 Elsevier Ireland Ltd. All rights reserved.
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alignant neoplasms of the central nervous system express
bnormally high levels of nitric oxide synthase (NOS) [5] sug-
esting that nitric oxide (NO) and related nitrogen species may
e associated with pathophysiological processes important to
hese tumours. NO can diffuse from the site of production and
an interact with superoxide to generate peroxynitrite, a highly
eactive species that may be responsible for nitration of tyro-
ine residues in proteins to form 3-nitrotyrosine [13]. Tyrosine
itration may lead to profound structural alterations with losses
n specific biological functions and enhanced proteolytic degra-
ation by the proteasome [13,18]. However, moderate tyrosine
itration also occurs in healthy tissues without causing apparent
ysfunctions in target proteins [2]. Protein nitration was recently
uggested to be involved in signal transduction [13], cell differ-
ntiation [3] and normal embryo development [10].
Abbreviations: ES/MS, electrospray mass spectrometry; ES/MS/MS,
lectrospray tandem mass spectrometry; HPLC, high-performance liquid
hromatography; LC/MS/MS, liquid chromatography–electrospray tandem
ass spectrometry; MALDI-TOF, matrix-assisted laser desorption ionisa-
Increased levels of nitrated proteins have been detected in sev-
eral diseases [11,20] and in some forms of cancer [7,12]. Little
is known about the target proteins for endogenous nitration dur-
ing brain tumour progression, though elevated levels of nitrated
proteins, as well as increased expression of inducible NOS con-
stitute an established correlate of human gliomas [5,6,9]. A
candidate target for nitration is represented by the cytoskeletal
protein tubulin. Tubulin nitration is putatively involved in pro-
tein turnover through the tyrosination/detyrosination cycle [14].
When free 3-nitrotyrosine is present in the cell, it is irreversibly
incorporated into alpha-tubulin preventing its detyrosination
which is essential in cellular growth, differentiation and motility
[4,8]. Nitrotyrosination of alpha-tubulin induces alterations in
cell morphology and changes in microtubule organisation [8],
though recent data showed that 3-nitrotyrosine incorporation
into alpha-tubulin is reversible and not detrimental to cells [1].
In this regard, recovery mechanisms restoring basal levels of
functionally active alpha-tubulin appear to be operative in some
invertebrate systems [17].
In this paper, we used biochemical, immunohistochemical
and proteomic approaches to characterise endogenous proteinion/time of flight; NOS, nitric oxide synthase; SDS–PAGE, sodium dodecyl
ulfate–polyacrylamide gel electrophoresis; TFA, trifluoroacetic acid
∗ Corresponding author. Tel.: +39 081 5833276/293; fax: +39 081 7641355.
E-mail address: palumbo@szn.it (A. Palumbo).
nitration in human gliomas. We demonstrated that tubulin is a
target of nitration in these tumours with modification essentially
occurring at a specific tyrosine residue different from that pre-
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viously reported under physiologically relevant conditions in
PC12 cells [19].
Brain tumour specimens were obtained from patients oper-
ated on at the Neurosurgery Department, Second University of
Naples. All patients or legal guardians gave informed consent for
this study (according to the Declaration of Helsinki and the Insti-
tutional Review Board of the Second University of Naples). They
were given detailed information about the aim of the research,
experimental procedures and methodologies. Surgical decision-
making was independent of the present study. Tumour type and
grade were determined by histological assessment according to
the World Health Organisation criteria for the grading of brain
tumours. The grading system is grades I–IV. Grade I tumours are
the least malignant and grow only very slowly, whereas grade
IV tumours are more malignant and grow faster.
Patient 1: 56-year-old male, left fronto-temporal craniotomy.
A rosaceous lesion infiltrating the temporal tip was excised.
Histological examination showed low-to-mild proliferation of
pseudo-spongioblastic glial fibrillar acidic protein-positive ele-
ments with Rosenthal fibres. Diagnosis: grade I pilocytic astro-
cytoma.
Patient 2: 45-year-old male, who underwent left frontal cran-
iotomy to remove a frontal lesion (3 cm diameter) localised
by echo guidance at a depth of 2 cm. Histological examination
showed high proliferation of cells with monotonous round nuclei



























phenylmethylsulfonyl fluoride. Homogenates were centrifuged
at 18,000 × g for 20 min and the extracts were subjected to west-
ern blotting for nitrated protein analysis. Protein concentration
was determined using a Bio-Rad protein assay reagent (Bio-Rad,
Milan, Italy) with bovine serum albumin as a standard.
Sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (SDS–PAGE) was carried out as reported [17] using an
acrylamide concentration of 7.5%. Rabbit polyclonal antibody
against 3-nitrotyrosine (1:1000) (Chemicon) was used.
For immunohistochemistry, tissues were treated as previously
described [17]. The primary antibodies were rabbit polyclonal
antibody against 3-nitrotyrosine (1:100) (Chemicon) and mouse
monoclonal anti-alpha-tubulin (1: 5000) (Sigma).
Coomassie blue-stained protein bands were excised from
SDS gels and in situ digested as described previously [15].
Matrix-assisted laser desorption ionisation/time of flight
(MALDI-TOF) mass spectra were recorded using an Applied
Biosystem Voyager DE-PRO instrument. A mixture of ana-
lyte and matrix solution (alfa-cyano-hydroxycinnamic acid
10 mg/ml in 66% acetonitrile, 0.1% TFA, in MilliQ water) was
applied to the metallic sample plate and dried down at room
temperature. Mass calibration was performed using external
peptide standards. Raw data were analysed using the computer
software provided by the manufacturer and reported as monoiso-
topic masses. Peptide masses of each digested protein were used






























Patient 3: 53-year-old male, operated for right frontal
lioblastoma 2 years earlier, who underwent right frontal cran-
otomy for a recurrent tumour. An intraoperative ecography
ocalised a neoplasm at 1 cm depth from the smooth frontal
erebral circumvolutions. Histological examination showed pro-
iferation of anaplastic elements with high mitotic activity and
eovascularisation as well as areas of necrosis. Diagnosis: grade
V glioblastoma.
Patient 4: 64-year-old male, left frontoparietal craniotomy.
he lesion (3 cm maximal diameter) was localised with echo
uidance at a depth of 2 cm. Histological examination showed
igh proliferation of small lymphocyte-like elements with high
itotic activity and frequent necrotic areas and pseudorosette.
iagnosis: grade IV glioblastoma.
Patient 5: 79-year-old female, parieto-occipital craniotomy.
rosaceous cortical–sub-cortical neoplasm was completely
emoved. Histological examination showed high proliferation
f glial anaplastic and plurinucleate elements with prolifera-
ion of vessels, and haemorrhagic areas. Diagnosis: grade IV
lioblastoma.
Pathological specimens obtained from neurosurgery were
ither frozen immediately at −80 ◦C and analysed within 1 day,
r prepared for immunohistochemistry. Trypsin, dithiothreitol,
odoacetamide and -cyano-4-hydroxycinnamic acid were pur-
hased from Sigma. High-performance liquid chromatography
HPLC) grade trifluoroacetic acid (TFA) was from Carlo Erba.
ll other reagents and solvents were from Baker and were of the
ighest purity available.
Brain samples were homogenised in 25 mM Tris buffer
pH 7.4) containing 100 mM NaCl, 1 mM EDTA and 1 mMerprinting softwares available on the net: MsFit from Protein
rospector, Mascot from Matrix Science and ProFound from
rowl.
Tryptic peptide mixtures obtained from in situ
igestions were also analysed by “on-line” Liquid
hromatography–Electrospray Tandem Mass Spectrome-
ry (LC/MS/MS) using an LCQ ion trap instrument (Finnigan
orp., San Jose´, CA, USA). Proteolytic digests were frac-
ionated on a HP 1100 HPLC apparatus (Hewlett-Packard,
alo Alto, CA, USA) using a narrowbore Phenomenex Jupiter
18 column (250 mm × 2.1 mm, 300 A˚) (Torrance, CA, USA)
ith 0.05% TFA, 5% formic acid in MilliQ water (solvent
) and 0.05% TFA, 5% formic acid in acetonitrile (solvent
) by means of a linear gradient from 5 to 70% solvent B in
0 min at a flow rate of 0.2 ml/min. The effluent was directly
nserted into the ion source through the electrospray probe and
oth electrospray mass spectrometry (ES/MS) and electrospray
andem mass spectrometry (ES/MS/MS) spectra were acquired
hroughout the entire analysis by using the software provided
ith the instrument.
Protein nitration was determined in five brain tumour sur-
ical specimens, including astrocytomas, oligodendrogliomas
nd highly malignant glioblastomas. Elevated tyrosine nitra-
ion was observed in all tumours as determined by nitrotyro-
ine immunoreactivity. However, significant differences were
bserved in individual samples as reported in Fig. 1. In astro-
ytoma (grade I), immunoreactivity to nitrotyrosine was con-
ned to few glial cells of different size. Some neurones showed
ositive immunoreaction, and no response was observed in
he stroma (Fig. 1A). In oligodendroglioma (grade II) glial
ells exhibited cytoplasmic immunoreactivity to nitrotyrosine. A
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Fig. 1. 3-Nitrotyrosine immunohistochemical staining of human gliomas. (A) Astrocytoma (grade I). Immunoreactivity is confined to spherical glial cells. Stain
was absent in the stroma. (B) Oligodendroglioma (grade II). Immunoreactivity is present in glial cells and a weak stain is present in the stroma. (C) Representative
glioblastoma (grade IV; sample 5). Immunoreactivity is present in many glial and neuronal elements. Note the very intense immunostaining in the stroma. (D)
Pre-absorption of anti-3-nitrotyrosine with 3-nitrotyrosine as control completely blocked immunostaining. (E) Sections of areas of minimally invaded brain from the
same pathological sections of the glioma patients stained with antibodies to 3-nitrotyrosine. Little or no nitration was observed. Scale bars = 100m.
weak and diffuse immunoreactivity was observed in the stroma
(Fig. 1B). In all samples of malignant glioblastomas (grade IV)
which are characterised by rapid growth, vascular proliferation
and oedema, and express relatively high levels of NOS I and
NOS II [5] the patterns of nitrotyrosine immunoreactivity were
similar. Strong nitrotyrosine immunopositivity was present in
many glial as well as neuronal elements (Fig. 1C). In some cases
immunopositive cells seemed to be plurinucleated. Along the
necrosis areas, immunoreactive elements were organised as clus-
ters. Strong immunoreactivity was also observed in the stroma.
Pre-incubation of the nitrotyrosine antibody with 3-nitrotyrosine
as control completely blocked immunostaining from a serial sec-
tion of the same tumour (Fig. 1D). Little or no nitration was
observed in areas of minimally invaded brain from the same
pathological sections of the glioma patients (Fig. 1E).
Investigation on the presence of alpha-tubulin in the same
samples assayed for nitrotyrosine immunoreactivity was per-
formed using specific anti-tubulin antibodies (Fig. 2). Tubu-
lin immunoreactivity was normally observed in both neuronal
and glial elements. However, immunohistochemical analyses
revealed that tubulin location within the different classes of
elements changes as the degree of malignancy increases, indi-
cating a non-uniform expression of the antigen. In fact, in both
astrocytoma (grade I, Fig. 2A) and oligodendroglioma (grade II,
Fig. 2B), as well as in not invaded areas (Fig. 2E), immunopos-
itivity to the alpha-tubulin was identified in neuronal elements,
especially fibres and nerve endings. In the oligodendroglioma,
however, some glial cells displayed an intense immunostaining
(Fig. 2B). In the malignant glioblastoma (grade IV), even though
immunoreactivity is still present in the neuronal elements, tubu-
lin was strongly immunodetected in the glial elements (Fig. 2C).
Controls performed by omitting primary antibody revealed no
tubulin immunoreactivity (Fig. 2D).
Identification of nitrated proteins in tumour samples was
accomplished by proteomic approaches. Protein extracts from
the five brain tumour samples were fractionated by SDS–PAGE
(Fig. 3). All extracts exhibited well-detectable nitrated protein
bands at 33 (a), 40 (b) and 55 kDa (e), four showed an additional
band at 45 kDa (c) and one had a distinct band at 50 kDa (d).
The Coomassie-stained bands corresponding to the immunore-
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Fig. 2. Alpha-tubulin immunoreactivity in human gliomas. (A) Astrocytoma (grade I). Immunoreactivity is present in fibres and nerve endings. (B) Oligodendroglioma
(grade II). Immunoreactivity is mainly present in fibres, but some glial cells show immunoreactivity (arrow). (C) Glioblastoma (grade IV; sample 5). Alpha-tubulin
strong immunopositivity is widely distributed to many glial (arrows) and neuronal elements. (D) Omission of anti-alpha-tubulin as control completely blocked
immunostaining. (E) Sections of areas of minimally invaded brain from the same pathological sections of the glioma patients stained with antibodies to alpha-tubulin.
Immunostaining is present in fibres. Scale bars = 70m in (A and C); 150m in (B, D and E).
active proteins were excised from the gels, reduced, alkylated
and in situ digested with trypsin. Fig. 4 shows the partial MALDI
mass spectrum of a peptide mixture from the tryptic digest of the
55 kDa protein from sample 4, taken as representative sample.
Mass signals were used to search for a non-redundant sequence
database using three different softwares available on the net,
taking advantage of the specificity of trypsin and the taxonomic
category of the sample. The set of mass values was compared
to the theoretically predicted peptides from the proteins in the
explored database. A set of 17 mass values matched within
human tubulin alpha 6 sequence with a mass accuracy better
than 80 ppm.
Fig. 3. SDS electrophoresis of protein extracts from brain tumour samples. Lanes 1A–5A: Coomassie-stained gels. Lanes 1B–5B: Western Blot. Lane numbers
correspond to patient identification numbers.
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Fig. 4. Partial MALDI mass spectrum of the peptide digest from the band at 55 kDa. Mass signals were assigned to the corresponding peptides within tubulin alpha
6 sequence on the basis of their mass values. Nitrated 216–229 peptide is indicated with (NO2). Trypsin autoproteolysis peaks are marked with an asterisk (*).
All the other putative candidates received a very low prob-
ability score, thus leading to the identification of tubulin as
the protein component. The mass spectral analysis led to a
sequence coverage of the tubulin primary structure greater than
46%. Moreover, investigation of the MALDI spectrum led to
the identification of the nitration site. Two related signals at m/z
1763. 9 and 1718.9, respectively, were detected in the spectrum
that exhibited a mass difference of 45 Da, corresponding to a
nitro group. The peak m/z 1718.9 was assigned to the fragment
216–229 within tubulin sequence whereas the satellite signal at
m/z 1763.9 corresponded to the peptide carrying a 3-nitro tyro-
sine residue. Since this fragment contains a single Tyr residue
at position 224, the modification site was unambiguously deter-
mined.
Although a high percentage of the protein sequence could
be mapped by MALDI mass fingerprinting, some sequence por-
tions escaped identification. The peptide mixture was then sub-
mitted to LC/MS/MS analysis. The peptide sequences obtained
from the interpretation of tandem mass spectra were used to con-
firm MALDI identification and led to an increase in the sequence
coverage which raised to 53%. Several tyrosine containing pep-
tides were identified by the mass spectrometric procedures, thus
leading to the identification of 10 Tyr residues that resulted to
be unmodified (Tyr 83, Tyr 103, Tyr 108, Tyr 262, Tyr 272, Tyr
312, Tyr 319, Tyr 357, Tyr 393, Tyr 408). However, a few tyro-











glioblastoma sample whereas this peak was completely absent
in the low-grade tumour sample. The remaining portions of the
spectra of the two samples were almost identical. Similarly,
the mass signals corresponding to the nitropeptide 216–229
were detected in the other glioblastoma samples. No detectable
tyrosine nitration was observed in the peptide 216–229 in non-
cancerous brain tissue (data not shown).
In this study we reported immunohistochemical evidence
indicating elevated protein nitration and tubulin expression in
Fig. 5. Partial MALDI mass spectrum of the mixtures from the tryptic digest of
the tubulin band in malignant glioblastoma (grade IV; sample 4, panel a) and in
astrocytoma (grade I; sample 1, panel b).ould not be monitored.
The presence of tubulin in the protein extracts from the
emaining four brain tumours (samples 1, 2, 3 and 5) was
ssessed using the same procedure. However, different results
n the occurrence of 3-nitrotyrosine in tubulin in the different
umour grades were obtained. As an example, Fig. 5 shows the
artial MALDI spectrum of the peptide mixtures from the tryp-
ic digest of the tubulin band in malignant glioblastoma (grade
V; sample 4, panel a) and in astrocytoma (grade I; sample 1,
anel b). The mass signal corresponding to the nitrated form of
he peptide 216–229 was clearly detected at m/z 1763.9 in the
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human gliomas compared to non-cancerous brain tissues, with
an apparently higher immunochemical response in glioblastoma
(grade IV) samples. Tubulin immunoreactivity becomes maxi-
mal in the glial elements as the neoplasm progresses, mirroring
the results of nitrotyrosine immunodetection. Finally, both anti-
gens are extremely immunoreactive in glial cells in advanced
grade tumours.
Proteomic investigation of protein extracts from grade IV
tumour tissues provided direct evidences that tubulin is nitrated
under severely pathological conditions. In particular, peptide
mass fingerprinting procedures allowed us to identify Tyr224
as a specific nitration site of alpha-tubulin in grade IV human
glioma samples. On the contrary, this residue was found to be
unmodified in lower grade tumours, e.g. astrocytoma (grade I)
or in control tissues. To the best of our knowledge, this is the
first identification of an in vivo site of endogenous nitration of
alpha-tubulin in human tumour tissues. Mass spectral analyses
led to the identification of 10 further Tyr residues that were found
unmodified.
Alpha-tubulin contains 18 or 19 tyrosine residues depend-
ing on the presence of the C-terminal tyrosine which can be
lost following specific proteolytic processing events [21]. These
residues are not equally susceptible to nitration, and several
structural factors responsible for selective post-translational
modification have been proposed. A mass spectrometric char-
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